Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bimagrumab · 3 trials · 5 indications
Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| Arm | Type | Description |
|---|---|---|
| Part A: Bimagrumab Dose 2 + Tirzepatide Placebo | EXPERIMENTAL | Participants will receive bimagrumab subcutaneously (SC) and tirzepatide placebo SC |
| Part A: Bimagrumab Placebo + Tirzepatide Dose 1 | ACTIVE_COMPARATOR | Participants will receive bimagrumab placebo SC and tirzepatide SC |
| Part A: Bimagrumab Placebo + Tirzepatide Dose 2 | ACTIVE_COMPARATOR | Participants will receive bimagrumab placebo SC and tirzepatide SC |
| Part A: Bimagrumab Dose 1 + Tirzepatide Dose 1 | EXPERIMENTAL | Participants will receive bimagrumab SC and tirzepatide SC |
| Part A: Bimagrumab Dose 1 + Tirzepatide Dose 2 | EXPERIMENTAL | Participants will receive bimagrumab SC and tirzepatide SC |
| Part A: Bimagrumab Dose 2 + Tirzepatide Dose 2 | EXPERIMENTAL | Participants will receive bimagrumab SC and tirzepatide SC |
| Part A: Bimagrumab Placebo + Tirzepatide Placebo | PLACEBO_COMPARATOR | Participants will receive bimagrumab placebo SC and tirzepatide placebo SC |
| Part B: Bimagrumab Dose 2 (no titration) + Tirzepatide Dose 1 | EXPERIMENTAL | Participants will receive bimagrumab SC and tirzepatide SC |
| Part B: Bimagrumab Dose 2 (fast titration) + Tirzepatide Dose 1 | EXPERIMENTAL | Participants will receive bimagrumab SC and tirzepatide SC |
| Part B: Bimagrumab Dose 2 (slow titration) + Tirzepatide Dose 1 | EXPERIMENTAL | Participants will receive bimagrumab SC and tirzepatide SC |
| Part B: Bimagrumab Dose 1 + Tirzepatide Placebo | EXPERIMENTAL | Participants will receive bimagrumab SC and tirzepatide placebo SC |
| Part B: Bimagrumab Placebo + Tirzepatide Placebo | PLACEBO_COMPARATOR | Participants will receive bimagrumab placebo SC and tirzepatide placebo SC |
| Placebo/30 mg/kg Bimagrumab | PLACEBO_COMPARATOR | Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64. |
| 10/30 mg/kg Bimagrumab | EXPERIMENTAL | Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64. |
| 30 mg/kg Bimagrumab | EXPERIMENTAL | Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64. |
| Placebo + 1.0 mg Semaglutide | EXPERIMENTAL | Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg |
| Placebo + 2.4 mg Semaglutide | EXPERIMENTAL | Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg |
| 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | EXPERIMENTAL | Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg |
| 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | EXPERIMENTAL | Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg |
| 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | EXPERIMENTAL | Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg |
| 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | EXPERIMENTAL | Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg |
| Bimagrumab Dose 1 Reference Material | EXPERIMENTAL | Participants will receive a single dose of bimagrumab subcutaneously (SC) |
| Bimagrumab Dose 1 Test Material + Tirzepatide (Coadministration) | EXPERIMENTAL | Participants will receive a single dose of bimagrumab SC and a single dose of tirzepatide SC |
| Bimagrumab Dose 1 Test Material + Tirzepatide (Coformulation) | EXPERIMENTAL | Participants will receive a single dose of bimagrumab with tirzepatide SC |
| Bimagrumab Dose 2 Test Material + Tirzepatide (Coadministration) | EXPERIMENTAL | Participants will receive bimagrumab SC and tirzepatide SC for 4 weeks |
| Bimagrumab Dose 2 Test Material + Tirzepatide (Coformulation) | EXPERIMENTAL | Participants will receive bimagrumab with tirzepatide SC for 4 weeks |
| Name | Type | Description |
|---|---|---|
| Bimagrumab | DRUG | Administered SC |
| Tirzepatide | DRUG | Administered SC |
| Bimagrumab Placebo | DRUG | Administered SC |
| Tirzepatide Placebo | DRUG | Administered SC |
| Semaglutide | DRUG | Glucagon-like peptide-1 (GLP-1) receptor agonist |
| Placebo | OTHER | Placebo |
| Bimagrumab + Tirzepatide Coformulation | DRUG | Administered SC |
Inclusion Criteria: * Have a BMI of * ≥30 kilograms per square meter (kg/m2) or * ≥27 kg/m2 and \<30 kg/m2, with at least one of the following weight-related comorbidities: * Hypertension * Dyslipidemia * Cardiovascular disease * Obstructive sleep apnea * Have had a stable bod...
Top 20 of 32 competitors
Bimagrumab is an investigational antibody being studied for weight management in adults with obesity or overweight. It is also being evaluated in healthy participants. The drug is being tested alone and in combination with other weight-management medications, including semaglutide and tirzepatide.
Bimagrumab is a monoclonal antibody, indicated by its -mab suffix. It is being studied for its effects on weight management in obesity. The specific molecular target is not disclosed in the available clinical trial information.
Bimagrumab is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in weight management.
Bimagrumab is in Phase 1 clinical development. It has completed one Phase 1 trial in healthy participants and is also being studied in Phase 2 trials for obesity and overweight. The drug is investigational and has not been approved by regulatory authorities.
Bimagrumab has been studied in three clinical trials. NCT05616013 evaluated bimagrumab with semaglutide in overweight or obese adults. NCT06643728 is an active study of bimagrumab with tirzepatide in obesity. NCT06890611 was a completed Phase 1 study in healthy participants.
Yes, Bimagrumab is also known as LY3985863. Clinical trial records use both names to refer to the same investigational drug. In studies combining it with tirzepatide, the combination is sometimes referred to as LY900042.